Takuya Otsuka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Takuya Otsuka has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Akinobu Taketomi
Department of Gastroenterological Surgery I Hokkaido University Graduate School of Medicine Sapporo Japan
3 shared publications - Akihisa Nagatsu
Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan
2 shared publications - Hirofumi Kamachi
Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Japan
2 shared publications - Kiyohiko Hotta
Department of Renal and Genitourinary Surgery, Faculty of Medicine Hokkaido University Sapporo Japan
2 shared publications Nobuo Shinohara
Department of Urology, Hokkaido University Hospital, Sapporo, Japan
2 shared publications- Sari Iwasaki
Department of Pathology, Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo Japan
2 shared publications
Latest Publications
- Open Access
- 10 August 2026
- Published by SAGE Publications in Human & Experimental Toxicology
- Vol. 45
Association between cigarette smoke exposure and immunoproteasome suppression in vascular endothelial cells
Introduction: The immunoproteasome is integral to endothelial redox homeostasis and protein quality control; however, its modulation by cigarette smoke remains unclear. We investigated whether cigarette smoke extract (CSE) suppresses immunoproteasome expression and promotes oxidative and inflammatory activation in vascular endothelial cells (VECs). Methods: Mouse VECs were exposed to 1.0% CSE for 16 h or treated with the β5i-selective inhibitor ONX-0914 (0.5–1.0 μM, 24–36 h). mRNA expression levels of proteasome subunits, NADPH oxidase 4 (NOX4), and inflammatory mediators were assessed by quantitative PCR. Proteasomal activity and intracellular reactive oxygen species (ROS) were quantified using luminescent assays. β5i expression in small pulmonary arterioles (≤0.5 mm) from smokers (n = 10) and nonsmokers (n = 10) was analyzed by immunohistochemistry. Results: CSE significantly suppressed immunoproteasome expression, reducing β5i mRNA by 66% ± 4% ( p = 0.0037) and decreasing proteasomal activity. Treatment with ONX-0914 increased intracellular ROS and upregulated NOX4 and inflammatory mediators, including monocyte chemoattractant protein-1 (approximately 6- to 7-fold at 0.5 μM for 36 h). Reduced endothelial β5i expression was more frequent in smokers than in nonsmokers. Discussion: Cigarette smoke-associated β5i suppression is linked to endothelial oxidative stress and inflammation, suggesting a potential mechanism underlying smoking-related vascular dysfunction.
- 10 August 2026
- Published by SAGE Publications in Human & Experimental Toxicology
- Vol. 45
Open AccessAssociation between cigarette smoke exposure and immunoproteasome suppression in vascular endothelial cells
Introduction: The immunoproteasome is integral to endothelial redox homeostasis and protein quality control; however, its modulation by cigarette smoke remains unclear. We investigated whether cigarette smoke extract (CSE) suppresses immunoproteasome expression and promotes oxidative and inflammatory activation in vascular endothelial cells (VECs). Methods: Mouse VECs were exposed to 1.0% CSE for 16 h or treated with the β5i-selective inhibitor ONX-0914 (0.5–1.0 μM, 24–36 h). mRNA expression levels of proteasome subunits, NADPH oxidase 4 (NOX4), and inflammatory mediators were assessed by quantitative PCR. Proteasomal activity and intracellular reactive oxygen species (ROS) were quantified using luminescent assays. β5i expression in small pulmonary arterioles (≤0.5 mm) from smokers (n = 10) and nonsmokers (n = 10) was analyzed by immunohistochemistry. Results: CSE significantly suppressed immunoproteasome expression, reducing β5i mRNA by 66% ± 4% ( p = 0.0037) and decreasing proteasomal activity. Treatment with ONX-0914 increased intracellular ROS and upregulated NOX4 and inflammatory mediators, including monocyte chemoattractant protein-1 (approximately 6- to 7-fold at 0.5 μM for 36 h). Reduced endothelial β5i expression was more frequent in smokers than in nonsmokers. Discussion: Cigarette smoke-associated β5i suppression is linked to endothelial oxidative stress and inflammation, suggesting a potential mechanism underlying smoking-related vascular dysfunction.
- 14 April 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (7)
Primary Cutaneous Secretory Carcinoma of the Eyelid Margin: A Case Report
- 14 April 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (7)
Primary Cutaneous Secretory Carcinoma of the Eyelid Margin: A Case Report
- Open Access
- 31 August 2023
- Published by Springer Nature in Surgical Case Reports
- Vol. 9 (1) , 1-6
Early-stage sigmoid colon cancer resection followed by liver metastasis recurrence 1 year later and mesenteric recurrence more than 5 years later: a case report
Background: Early-stage colorectal cancer (CRC) is often treated endoscopically, but additional surgical resection may be considered depending on pathological findings. Case presentation: A 73-year-old man was found to have early-stage sigmoid colon cancer by colonoscopy during a medical examination, and endoscopic mucosal resection (EMR) was performed. The lesion was a 7-mm-sized sessile polyp, and the pathological diagnosis was well-differentiated tubular adenocarcinoma, pT1 (submucosal invasion of 400 μm), with no lymphovascular invasion, low budding grade, and negative horizontal and vertical margins. Therefore, the patient was observed without postoperative treatment. One year later, a computed tomography (CT) scan showed multiple liver metastases. After five courses of preoperative chemotherapy with folinic acid, 5-fluorouracil and oxaliplatin (FOLFOX) and panitumumab, liver metastases were reduced. The patient underwent extended right hepatic lobectomy. The pathological finding was well-to-moderately differentiated tubular adenocarcinoma, and immunohistochemistry findings were consistent with liver metastases from sigmoid colon cancer. Postoperatively, the patient received five courses adjuvant chemotherapy with FOLFOX. Although the patient had been recurrence-free for 5 years after liver resection, a CT scan revealed a nodular lesion in the sigmoid mesentery. Positron emission tomography (PET) showed abnormal accumulation in the same lesion. Therefore, the mesenteric nodules diagnosed as lymph metastasis and recurrence of sigmoid colon cancer and performed laparoscopic sigmoid colon resection with lymph node dissection. The pathological findings showed that the recurrent lesion in the mesentery formed a nodular infiltrate with venous, lymphatic, and neural invasion, but lymph node structures were not found, and it was assumed to be metastasis or recurrence due to lymphovascular invasion. The pathologic specimen of the sigmoid colon had no neoplastic lesions, which are considered to be a local recurrence on the mucosal surface. After sigmoid colectomy, adjuvant chemotherapy with CapeOX was conducted, and the patient has been recurrence-free for 13 months at present. Conclusion: Even early-stage CRCs that have no pathological indications for additional resection have risks of metastases and recurrences, and we may need to consider that the criteria for additional resection should not be limited to pathological findings alone.
- 31 August 2023
- Published by Springer Nature in Surgical Case Reports
- Vol. 9 (1) , 1-6
Open AccessEarly-stage sigmoid colon cancer resection followed by liver metastasis recurrence 1 year later and mesenteric recurrence more than 5 years later: a case report
Background: Early-stage colorectal cancer (CRC) is often treated endoscopically, but additional surgical resection may be considered depending on pathological findings. Case presentation: A 73-year-old man was found to have early-stage sigmoid colon cancer by colonoscopy during a medical examination, and endoscopic mucosal resection (EMR) was performed. The lesion was a 7-mm-sized sessile polyp, and the pathological diagnosis was well-differentiated tubular adenocarcinoma, pT1 (submucosal invasion of 400 μm), with no lymphovascular invasion, low budding grade, and negative horizontal and vertical margins. Therefore, the patient was observed without postoperative treatment. One year later, a computed tomography (CT) scan showed multiple liver metastases. After five courses of preoperative chemotherapy with folinic acid, 5-fluorouracil and oxaliplatin (FOLFOX) and panitumumab, liver metastases were reduced. The patient underwent extended right hepatic lobectomy. The pathological finding was well-to-moderately differentiated tubular adenocarcinoma, and immunohistochemistry findings were consistent with liver metastases from sigmoid colon cancer. Postoperatively, the patient received five courses adjuvant chemotherapy with FOLFOX. Although the patient had been recurrence-free for 5 years after liver resection, a CT scan revealed a nodular lesion in the sigmoid mesentery. Positron emission tomography (PET) showed abnormal accumulation in the same lesion. Therefore, the mesenteric nodules diagnosed as lymph metastasis and recurrence of sigmoid colon cancer and performed laparoscopic sigmoid colon resection with lymph node dissection. The pathological findings showed that the recurrent lesion in the mesentery formed a nodular infiltrate with venous, lymphatic, and neural invasion, but lymph node structures were not found, and it was assumed to be metastasis or recurrence due to lymphovascular invasion. The pathologic specimen of the sigmoid colon had no neoplastic lesions, which are considered to be a local recurrence on the mucosal surface. After sigmoid colectomy, adjuvant chemotherapy with CapeOX was conducted, and the patient has been recurrence-free for 13 months at present. Conclusion: Even early-stage CRCs that have no pathological indications for additional resection have risks of metastases and recurrences, and we may need to consider that the criteria for additional resection should not be limited to pathological findings alone.
- Open Access
- 5 June 2023
- Published by S. Karger AG in Nephron
- Vol. 147 (Suppl. 1) , 41-45
Exacerbation of Intimal Fibrosis and Endarteritis in a Kidney Transplant Recipient with Chronic Active Antibody-Mediated Rejection and COVID-19: A Case Report
Kidney transplant recipients are immunocompromised hosts at risk for comorbidity and mortality due to infection. Currently, there are no established guidelines for the management of immunosuppressed transplant recipients with coronavirus disease 2019 (COVID-19). The impact of COVID-19 and its therapeutic management on chronic active antibody-mediated rejection (CAAMR) are still unclear. Here, we report a case of CAAMR exacerbation with endarteritis and intimal fibrosis after COVID-19. A 41-year-old female kidney transplant recipient with CAAMR was admitted to a local hospital with moderately severe COVID-19. Her doses of tacrolimus and mycophenolate mofetil were reduced, and she was administered methylprednisolone pulse and antiviral drugs. This resulted in a good clinical course and she was discharged in 15 days. During and after hospitalization, the immunosuppressants were gradually returned to the baseline levels. However, about 1.5 months after discharge, the serum creatinine level became elevated. An indication kidney biopsy showed CAAMR with intimal fibrosis and endarteritis in all interlobular arteries. An increase of immunosuppressant led to a decrease of the serum creatinine level. Factors contributing to CAAMR with intimal fibrosis and endarteritis may include (1) insufficient immunosuppression due to changes in the levels of immunosuppressive; (2) overlap with endothelial cell injury caused by COVID-19, and (3) an immune-activated state associated with COVID-19. COVID-19 is a life-threatening disease that can result in unexpected changes in immunological status. Possible allograft rejection should be carefully managed in such patients.
- 5 June 2023
- Published by S. Karger AG in Nephron
- Vol. 147 (Suppl. 1) , 41-45
Open AccessExacerbation of Intimal Fibrosis and Endarteritis in a Kidney Transplant Recipient with Chronic Active Antibody-Mediated Rejection and COVID-19: A Case Report
Kidney transplant recipients are immunocompromised hosts at risk for comorbidity and mortality due to infection. Currently, there are no established guidelines for the management of immunosuppressed transplant recipients with coronavirus disease 2019 (COVID-19). The impact of COVID-19 and its therapeutic management on chronic active antibody-mediated rejection (CAAMR) are still unclear. Here, we report a case of CAAMR exacerbation with endarteritis and intimal fibrosis after COVID-19. A 41-year-old female kidney transplant recipient with CAAMR was admitted to a local hospital with moderately severe COVID-19. Her doses of tacrolimus and mycophenolate mofetil were reduced, and she was administered methylprednisolone pulse and antiviral drugs. This resulted in a good clinical course and she was discharged in 15 days. During and after hospitalization, the immunosuppressants were gradually returned to the baseline levels. However, about 1.5 months after discharge, the serum creatinine level became elevated. An indication kidney biopsy showed CAAMR with intimal fibrosis and endarteritis in all interlobular arteries. An increase of immunosuppressant led to a decrease of the serum creatinine level. Factors contributing to CAAMR with intimal fibrosis and endarteritis may include (1) insufficient immunosuppression due to changes in the levels of immunosuppressive; (2) overlap with endothelial cell injury caused by COVID-19, and (3) an immune-activated state associated with COVID-19. COVID-19 is a life-threatening disease that can result in unexpected changes in immunological status. Possible allograft rejection should be carefully managed in such patients.
- 11 May 2023
- Published by S. Karger AG in Nephron
- Vol. 147 (10) , 621-626
Use of Mixed Lymphocyte Reaction Assay to Evaluate Immune Tolerance before Kidney Transplantation with an Immunosuppression-Free Protocol following Hematopoietic Stem Cell Transplantation from the Same Donor
Several cases of kidney transplantation after hematopoietic stem cell transplantation (HSCT) from the same donor for end-stage renal disease have been reported. In those cases, immunosuppressive drugs were discontinued since immune tolerance was supposed to be induced. Theoretically, the recipient’s immune system recognizes the kidney allograft as its own tissue with the same human leukocyte antigen (HLA) profile, and the kidney allograft will not be rejected, even without the use of immunosuppressive agents. However, almost all recipients receive immunosuppressants in the early stages after kidney transplantation owing to concerns of acute rejection. Here, we report a successful case of post-HSCT kidney transplantation without the use of immunosuppressive drugs, in which a mixed lymphocyte reaction (MLR) assay was used to evaluate immune tolerance before kidney transplantation. The patient was a 25-year-old woman. Five years prior, she developed acute myeloid leukemia and underwent HLA-half-matched peripheral blood stem cell transplantation. Thereafter, she was in remission of the acute myeloid leukemia, but 1 year later, she developed renal graft-versus-host disease. Subsequently, the patient’s renal function gradually deteriorated to end-stage renal failure, and she underwent kidney transplantation with the previous stem cell donor: her mother. HLA typing of donor and recipient showed a complete chimerism in the peripheral blood. The pretransplantation complement-dependent cytotoxic crossmatch and flow cytometric T-cell crossmatch results were both negative, and HLA antibody measurements were all negative. The MLR assay revealed no T-lymphocyte reaction to the donor; therefore, immunosuppressants were not used. Two years after transplantation, the patient’s serum creatinine concentration was around 0.8 mg/dL (down from 4 mg/dL before transplantation). No abnormalities were observed in a renal biopsy performed after 3 months. Our study, along with others, indicates that immune tolerance to a donor develops in post-HSCT kidney transplantation from the same donor.
- 11 May 2023
- Published by S. Karger AG in Nephron
- Vol. 147 (10) , 621-626
Use of Mixed Lymphocyte Reaction Assay to Evaluate Immune Tolerance before Kidney Transplantation with an Immunosuppression-Free Protocol following Hematopoietic Stem Cell Transplantation from the Same Donor
Several cases of kidney transplantation after hematopoietic stem cell transplantation (HSCT) from the same donor for end-stage renal disease have been reported. In those cases, immunosuppressive drugs were discontinued since immune tolerance was supposed to be induced. Theoretically, the recipient’s immune system recognizes the kidney allograft as its own tissue with the same human leukocyte antigen (HLA) profile, and the kidney allograft will not be rejected, even without the use of immunosuppressive agents. However, almost all recipients receive immunosuppressants in the early stages after kidney transplantation owing to concerns of acute rejection. Here, we report a successful case of post-HSCT kidney transplantation without the use of immunosuppressive drugs, in which a mixed lymphocyte reaction (MLR) assay was used to evaluate immune tolerance before kidney transplantation. The patient was a 25-year-old woman. Five years prior, she developed acute myeloid leukemia and underwent HLA-half-matched peripheral blood stem cell transplantation. Thereafter, she was in remission of the acute myeloid leukemia, but 1 year later, she developed renal graft-versus-host disease. Subsequently, the patient’s renal function gradually deteriorated to end-stage renal failure, and she underwent kidney transplantation with the previous stem cell donor: her mother. HLA typing of donor and recipient showed a complete chimerism in the peripheral blood. The pretransplantation complement-dependent cytotoxic crossmatch and flow cytometric T-cell crossmatch results were both negative, and HLA antibody measurements were all negative. The MLR assay revealed no T-lymphocyte reaction to the donor; therefore, immunosuppressants were not used. Two years after transplantation, the patient’s serum creatinine concentration was around 0.8 mg/dL (down from 4 mg/dL before transplantation). No abnormalities were observed in a renal biopsy performed after 3 months. Our study, along with others, indicates that immune tolerance to a donor develops in post-HSCT kidney transplantation from the same donor.
- Open Access
- 21 March 2022
- Published by Springer Nature in Surgical Case Reports
- Vol. 8 (1) , 1-7
Laparoscopic liver resection for liver metastasis of leiomyosarcoma of the thigh: a case report
Background: Although there is no established treatment strategy for liver metastasis of leiomyosarcoma, liver resection has been reported to be effective in some cases. However, almost all liver resections performed for liver metastasis of primary leiomyosarcoma are reported to be open resections, and there are few reports of liver resection performed by laparoscopy. Here, we report a case of laparoscopic liver resection for liver metastasis of a leiomyosarcoma in the right thigh. Case presentation: An 80-year-old man was diagnosed with leiomyosarcoma of the right thigh with liver metastasis. The primary tumor was first resected, and he was discharged on the 25th postoperative day. Four months after primary tumor resection, a laparoscopic right posterior sectionectomy was performed. There were no postoperative complications, and the patient was discharged on the 11th postoperative day with a histopathological diagnosis of liver metastasis of leiomyosarcoma and negative resection margins. Currently, 9 months have passed since the resection of the primary tumor, and 5 months have passed since the laparoscopic liver resection; there is no recurrence. Conclusions: The liver metastasis of leiomyosarcoma was successfully removed, with good short-term outcomes after the laparoscopic liver resection. Laparoscopic liver resection seems to be effective for liver metastasis of leiomyosarcoma, which is characterized by a high recurrence rate after surgery. However, more case studies may be necessary to examine the effectiveness and long-term results of laparoscopic liver resection for the treatment of liver metastasis of leiomyosarcoma.
- 21 March 2022
- Published by Springer Nature in Surgical Case Reports
- Vol. 8 (1) , 1-7
Open AccessLaparoscopic liver resection for liver metastasis of leiomyosarcoma of the thigh: a case report
Background: Although there is no established treatment strategy for liver metastasis of leiomyosarcoma, liver resection has been reported to be effective in some cases. However, almost all liver resections performed for liver metastasis of primary leiomyosarcoma are reported to be open resections, and there are few reports of liver resection performed by laparoscopy. Here, we report a case of laparoscopic liver resection for liver metastasis of a leiomyosarcoma in the right thigh. Case presentation: An 80-year-old man was diagnosed with leiomyosarcoma of the right thigh with liver metastasis. The primary tumor was first resected, and he was discharged on the 25th postoperative day. Four months after primary tumor resection, a laparoscopic right posterior sectionectomy was performed. There were no postoperative complications, and the patient was discharged on the 11th postoperative day with a histopathological diagnosis of liver metastasis of leiomyosarcoma and negative resection margins. Currently, 9 months have passed since the resection of the primary tumor, and 5 months have passed since the laparoscopic liver resection; there is no recurrence. Conclusions: The liver metastasis of leiomyosarcoma was successfully removed, with good short-term outcomes after the laparoscopic liver resection. Laparoscopic liver resection seems to be effective for liver metastasis of leiomyosarcoma, which is characterized by a high recurrence rate after surgery. However, more case studies may be necessary to examine the effectiveness and long-term results of laparoscopic liver resection for the treatment of liver metastasis of leiomyosarcoma.
- 15 March 2022
- Published by Springer Nature in International Cancer Conference Journal
- Vol. 11 (3) , 178-183
Liver metastasis 13 years after the resection of a malignant triton tumor originating in the duodenum
This is an additional case report of a malignant triton tumor arising in the duodenum that was removed by pancreatoduodenectomy. Liver and gallbladder dysfunctions were detected in a regular blood examination during a follow-up for hypertension in a 62-year-old woman with a previous surgical history for a malignant Triton tumor in the duodenum 13 years ago. Further examinations revealed a metastatic liver tumor originating from the malignant triton tumor in the duodenum. Since the progression of the liver tumor was detected after radiation therapy, complete resection was performed by right hepatectomy. Curative hepatectomy resulted in disease-free survival for 1 year and 5 months in an extremely rare case of liver metastasis derived from a malignant triton tumor in the duodenum.
- 15 March 2022
- Published by Springer Nature in International Cancer Conference Journal
- Vol. 11 (3) , 178-183
Liver metastasis 13 years after the resection of a malignant triton tumor originating in the duodenum
This is an additional case report of a malignant triton tumor arising in the duodenum that was removed by pancreatoduodenectomy. Liver and gallbladder dysfunctions were detected in a regular blood examination during a follow-up for hypertension in a 62-year-old woman with a previous surgical history for a malignant Triton tumor in the duodenum 13 years ago. Further examinations revealed a metastatic liver tumor originating from the malignant triton tumor in the duodenum. Since the progression of the liver tumor was detected after radiation therapy, complete resection was performed by right hepatectomy. Curative hepatectomy resulted in disease-free survival for 1 year and 5 months in an extremely rare case of liver metastasis derived from a malignant triton tumor in the duodenum.
- Open Access
- 20 August 2020
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 27 (8S) , S710-S712
Infliximab-Induced Granulomatous Vasculitis With Amyloid Deposition in the Tongue of a Patient With Behçet Disease
An abstract is unavailable. This article is available as a PDF only.
- 20 August 2020
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 27 (8S) , S710-S712
Open AccessInfliximab-Induced Granulomatous Vasculitis With Amyloid Deposition in the Tongue of a Patient With Behçet Disease
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 1 January 1995
- Published by Institute of Electrical Engineers of Japan (IEE Japan) in IEEJ Transactions on Power and Energy
- Vol. 115 (11) , 1387-1392
Development of Electric Field Optimization Technique Using Neural Network
- 1 January 1995
- Published by Institute of Electrical Engineers of Japan (IEE Japan) in IEEJ Transactions on Power and Energy
- Vol. 115 (11) , 1387-1392
Open AccessDevelopment of Electric Field Optimization Technique Using Neural Network